CCR2-64i and CCR5 Δ32 polymorphisms in patients with late-onset Alzheimer's disease; a study from Iran (CCR2-64i and CCr5 Δ32 polymorphisms in Alzheimer's disease)

Iranian Journal of Basic Medical Sciences

Volumn 15, Issue 4, 2012, Pages 937-944

  Khorshid, Hamid Reza Khorram ^a   Manoochehri, Mehdi ^a   Nasehi, Leila ^b   Ohadi, Mina ^a   Rahgozar, Mehdi ^a   Kamali, Koorosh ^b  

^a UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^b AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Alzheimer's disease; CCR2; CCR5; Genetic association study; Inflammation; Iranian population

Indexed keywords

APOLIPOPROTEIN E; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL ANALYSIS;

EID: 84863456109     PISSN: 20083866     EISSN: 20083874     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Selkoe DJ. Defining molecular targets to prevent Alzheimer's disease. Arch Neurol 2005; 62: 192-195.
2. Kamer AR, Craig RG, Dasanayake AP, Brys M, Glodzik-Sobanska L, Leon MJ. Inflammation and Alzheimer's disease: Possible role of periodontal diseases. Alzheimer Dement 2008; 4:242-250.
3. McGeer PL, McGeer EG. NSAIDs and Alzheimer's disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007; 639-647.
4. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA 2003; 289: 2819-2826.
5. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol 2007; 184:69-91.
6. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987; 79:195-200.
7. Perlmutter LS, Barron E, Chui HC. Morphologic association between microglia and senile plaque amyloid in Alzheimer's disease. Neurosci Lett 1990; 119:32-36.
8. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella JK, et al. CD36, a Class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to b-amyloid fibrils. Am J Pathol 2002; 160:101-112.
9. El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, et al. CD36 mediates the innate host response to b-amyloid. J Exp Med 2003; 197:1657-1666.
10. Haga S, Ikeda K, Sato M, Ishii T. Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res 1993; 601:88-94.
11. Moser B, Loetscher M, Piali L, Loetscher P. Lymphocyte responses to chemokines. Int Rev Immunol 1998; 16:323-344.
12. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12:121-127.
13. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18:217242.
14. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21:383-421.
15. Fantuzzi L, Borghi P, Ciolli V, Pavlakis G, Belardelli F, Gessani S. Loss Of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during the differentiation of human monocytes: role of secreted MCP-1 in the regulation of the chemotactic response. Blood 1999; 94:875-883.
16. Premack BA, Schall TJ. Chemokine receptors: gateways to inflammation and infection. Nat Med 1996, 2:1174-1178.
17. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998, 392:565-568.
18. Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, Fernández S, Martín de Ana A, Jones DR, et al. Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J 2001; 20:2497-507.
19. El Khoury J, Toft M, Hickman SE, Means TK, Terada K. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 2007; 13:432-438.
20. Zachariae CO, Anderson AO, Thompson HL, Appella E, Mantovani A, Oppenheim JJ, et al. Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J Exp Med 1990; 171:2177-2182.
21. Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 2008; 48:171-197.
22. Khoury JE, Luster AD. Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends in Pharmacological Sciences? 2008; 29:626-632.
23. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study of the -chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol 1998; 153:31-37.
24. Man SM, Ma YR, Shang DS, Zhao WD, Li B, Guo DW, et al. Peripheral T cells overexpress MIP-1α to enhance its transendothelial migration in Alzheimer's disease. Neurobiol Aging 2007; 28:485-496.
25. Gharagozloo M, Doroudchi M, Farjadian S, Pezeshki AM, Ghaderi A. The frequency of CCR5Delta32 and CCR2-64I in Southern Iranian normal population. Immunol Lett 2005; 96:277-281.
26. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997; 277:959-965.
27. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 367:77-86.
28. Galimberti D, Fenoglio C, Lovati C, Gatti A, Guidi I, Venturelli E, et al. CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer's disease. J Neurol Sci 2004; 225:79-83.
29. Huerta C, Alvarez V, Mata IF, Coto E, Ribacoba R, Martínez C, et al. Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neurosci Lett 2004; 370:151-154.
30. Combarros O, Infante J, Llorca J, Peña N, Fernández-Viadero C, Berciano J. The chemokine receptor CCR5-Δ32 gene mutation is not protective against Alzheimer's disease. Neurosci Lett 2004; 366:312-314.
31. Balistreri CR, Grimaldi MP, Vasto S, Listi F, Chiappelli M, Licastro F, et al. Association between the polymorphism of CCR5 and Alzheimer's disease: results of a study performed on male and female patients from Northern Italy. Ann N Y Acad Sci 2006; 1089:454-461.
32. Lampson LA. Molecular bases of the immune response to neural antigens. Trends Neuroscience; 10:211-216 1987.
33. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies. Bri Med J 2003; 327:128.
34. Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson's disease: A role in neurodegeneration? Ann Neurol 1998; 44:115-120.
35. Sorenson TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103:801-815.
36. Mohaddes Ardebili SM, Rezazadeh M, Gharesouran J, Yeghaneh T, Farhoudi M, Ayromlou H, et al. Association of CCR2 gene but not CCR5 gene polymorphisms with Alzheimer's disease. J Sci Islam Republic Iran 2011; 22:111-116.